Yuhan Corporation (KRX: 000100)
South Korea
· Delayed Price · Currency is KRW
119,500
+7,200 (6.41%)
Dec 30, 2024, 3:30 PM KST
Yuhan Revenue
Yuhan had revenue of 598.78B KRW in the quarter ending September 30, 2024, with 23.96% growth. This brings the company's revenue in the last twelve months to 2.01T, up 7.29% year-over-year. In the year 2023, Yuhan had annual revenue of 1.86T with 4.68% growth.
Revenue (ttm)
2,008.84B
Revenue Growth
+7.29%
P/S Ratio
4.67
Revenue / Employee
1.00B
Employees
1,999
Market Cap
8,925.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,858.98B | 83.14B | 4.68% |
Dec 31, 2022 | 1,775.85B | 88.04B | 5.22% |
Dec 31, 2021 | 1,687.81B | 67.95B | 4.19% |
Dec 31, 2020 | 1,619.87B | 139.51B | 9.42% |
Dec 31, 2019 | 1,480.35B | -38.47B | -2.53% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics Co.,Ltd. | 4,364.39B |
Celltrion | 2,876.25B |
SK Biopharmaceuticals | 511.33B |
SK bioscience Co.,Ltd. | 201.30B |
Hanmi Pharm. | 1,566.25B |
Hanall Biopharma | 134.24B |
Hanmi Science | 1,283.65B |
GC Biopharma | 1,643.98B |